Isis Pharmaceuticals, Inc.
1896 Rutherford Road
Carlsbad,
CA 92008-7208
United States - Map
Phone: 760-931-9200
Fax: 760-603-2700
Web Site: http://www.isispharm.com
| Isis Pharmaceuticals, Inc. engages in RNA-based drug discovery and development for its product pipeline and for its partners. It primarily offers Vitravene, an antisense drug to treat cytomegalovirus retinitis in AIDS patients. The company has approximately 19 drugs in development, including Mipomersen (ISIS 301012) for familial hypercholesterolemia patients; ISIS-CRPRx, an antisense drug; BMS-PCSK9Rx that targets proprotein convertase subtilisin/kexin type 9; OMJP-GCGR, a glucagon receptor; OMJP-GCCR, a glucocorticoid receptor; and ISIS-SGLT2Rx, which targets sodiumglucose co-transporter type 2. Its cancer products under development include OGX-011, a secreted protein that acts as a cell-survival protein; OGX-427, a drug targeting heat shock protein 27; LY2181308 that targets survivin; and LY2275796 for eukaryotic initiation factor-4E. Isis Pharmaceuticals also develops ISIS-SOD1Rx to treat amyotrophic lateral sclerosis; ACHN-490 for the treatment of multi-drug resistant gram-negative bacterial infections; AIR645 to treat respiratory conditions; Alicaforsen and ATL/TV1102 for the treatment of inflammatory disorders; ATL1103, a receptor that reduces the level of circulating insulin-like growth factor-1; EXC001 to treat fibrotic diseases; and iCo-007 for the treatment of various eye diseases. The company also focuses on the development and commercialization of microRNA therapeutics. It has strategic alliances/collaboration/licensing agreements with Genzyme Corporation; Ortho-McNeil-Janssen Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Pfizer Inc.; Eli Lilly and Company; Merck & Co., Inc.; Achaogen, Inc.; Altair Therapeutics Inc.; Antisense Therapeutics Limited; Atlantic Pharmaceuticals Limited; Excaliard Pharmaceuticals, Inc.; iCo Therapeutics Inc.; OncoGenex Technologies Inc.; Novosom AG; Archemix Corp.; Ercole Biotech, Inc.; Santaris Pharma A/S; and Alnylam Pharmaceuticals, Inc. The company was founded in 1989 and is based in Carlsbad, California. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. Stanley Crooke M.D., Ph.D., 63
Founder, Chairman, Chief Exec. Officer and Pres |
$
1.09M |
$
79.00K | Ms. B. Lynne Parshall J.D., 54
Chief Operating Officer, Chief Financial Officer, Principal Accounting Officer, Sec. |
$
863.00K |
$
15.00K | Dr. Kleanthis G. Xanthopoulos Ph.D., 50
Sr. VP, Chief Exec. Officer of Regulus Therapeutics Inc and Pres of Regulus Therapeutics Inc |
$
623.00K | N/A | Dr. C. Frank Bennett Ph.D., 52
Sr. VP of Antisense Research |
$
516.00K |
$
351.00K | Dr. Richard S. Geary Ph.D, 51
Sr. VP of Devel. |
$
450.00K |
$
34.00K |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.33% Nasdaq 
0.02 (0.13%) 
Profile
